Diabetes Dialogue: Diabetes Tech Updates from November 2024

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

In this episode of Diabetes Dialogue, hosts an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center discuss exciting updates in diabetes technology from November 2024.

First, they highlighted the newly announced collaboration between Dexcom and the Oura Ring, which promises to integrate glucose monitoring with insights from the wearable's advanced sleep and activity tracking. This partnership could provide actionable data for patients and clinicians, offering deeper insights into how factors like exercise, sleep, and stress affect glucose trends. While the integration is not yet live, both hosts express enthusiasm for its potential, especially for tools like the over-the-counter Dexcom Stelo CGM.

Next, they discuss the expanded compatibility of the OmniPod 5 system with Abbott's FreeStyle Libre 2 sensors, now available in the U.S. for use with the OmniPod's controller. This change introduces greater choice for users and enhances affordability by accommodating insurance-preferred sensors. They also address the rollout of OmniPod 5’s iPhone app for Dexcom G6, new preset bolus options for meals, and updated simulator tools, all designed to streamline workflows and improve patient outcomes. However, the hosts emphasize the need for careful coordination between pod types and CGM models during this transitional period.

Lastly, Isaacs and Bellini explore Medtronic’s new integration of the Simplera CGM with its InPen smart pen. This innovation provides trend-based correction dose recommendations, mirroring features of automated insulin delivery systems. With easier-to-use CGMs and connected pen options, this development could benefit patients preferring multiple daily injections or seeking breaks from pump therapy. The hosts underline how these advancements offer more personalized, flexible diabetes management solutions.

Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.